Skip to main content
SpringerLink
Log in

What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives

To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019.

Methods

Data were analyzed considering three time periods (1990–1999, 2000–2009, 2010–2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan–Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival.

Results

The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2–10.9), 9.0 (7.6–10.4) and 12.0 (10.5–13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000–2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival.

Conclusions

It was found that histopathological diagnosis and treatment success in MM have improved over the years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sirri E, Kieschke J, Vohmann C et al (2020) GEKID cancer survival working group, survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study. Int J Cancer 147(6):1548–1558. https://doi.org/10.1002/ijc.32931

    Article  CAS  PubMed  Google Scholar 

  2. Metintaş S, Batırel HF, Bayram H et al (2017) Turkey national mesothelioma surveillance and environmental asbestos exposure control program. Int J Environ Res Public Health 14(11):1293. https://doi.org/10.3390/ijerph14111293

    Article  PubMed Central  Google Scholar 

  3. Plato N, Martinsen JI, Sparén P et al (2016) Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban. Epidemiol Health 38:e2016039. https://doi.org/10.4178/epih.e2016039

    Article  PubMed  PubMed Central  Google Scholar 

  4. Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89(10):716–724. https://doi.org/10.2471/BLT.11.086678

    Article  PubMed  PubMed Central  Google Scholar 

  5. Metintas S, Metintas M, Ucgun I et al (2002) Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 122(6):2224–2229. https://doi.org/10.1378/chest.122.6.2224

    Article  PubMed  Google Scholar 

  6. Metintas S, Ak G, Metintas M (2019) A review of the cohorts with environmental and occupational mineral fiber exposure. Arch Environ Occup Health 74(1–2):76–84. https://doi.org/10.1080/19338244.2018.1467873

    Article  CAS  PubMed  Google Scholar 

  7. Galateau-Salle F, Churg A, Roggli V et al (2016) World Health Organization Committee for tumors of the pleura, the 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol 11(2):142–154. https://doi.org/10.1016/j.jtho.2015.11.005

    Article  PubMed  Google Scholar 

  8. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644. https://doi.org/10.1200/JCO.2003.11.136

    Article  CAS  PubMed  Google Scholar 

  9. Krug LM, Pass HI, Rusch VW et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27(18):3007–3013. https://doi.org/10.1200/JCO.2008.20.3943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Treasure T, Lang-Lazdunski L, Waller D et al (2011) MARS trialists, extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763–772. https://doi.org/10.1016/S1470-2045(11)70149-8

    Article  PubMed  PubMed Central  Google Scholar 

  11. LeStang N, Bouvier V, Glehen O et al (2019) Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: a population-based study. Cancer Epidemiol 60:106–111. https://doi.org/10.1016/j.canep.2019.03.014

    Article  CAS  Google Scholar 

  12. Baas P, Daumont MJ, Lacoin L et al (2021) Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: a nationwide CAS registry analysis from the I-O optimise initiative. Lung Cancer 162:185–193. https://doi.org/10.1016/j.lungcan.2021.11.001

    Article  CAS  PubMed  Google Scholar 

  13. Brambilla E, Travis WD, Colby TV et al (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18(6):1059–1068. https://doi.org/10.1183/09031936.01.00275301

    Article  CAS  PubMed  Google Scholar 

  14. Travis WD, Brambilla E, Burke AP et al (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10(2015):1240–1242. https://doi.org/10.1097/JTO.0000000000000663

    Article  PubMed  Google Scholar 

  15. Husain AN, Colby TV, Ordóñez NG et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 142(1):89–108. https://doi.org/10.5858/arpa.2017-0124-RA

    Article  CAS  PubMed  Google Scholar 

  16. Nicholson AG, Sauter JL, Nowak AK et al (2020) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 15(1):29–49. https://doi.org/10.1016/j.jtho.2019.08.2506

    Article  CAS  PubMed  Google Scholar 

  17. Galateau-Salle F, Churg A, Roggli V et al (2016) World Health Organization committee for tumors of the pleura, the 2015 World Health Organization classification of tumors of the pleura, advances since the 2004 classification. J Thorac Oncol 11(2):142–154. https://doi.org/10.1016/j.jtho.2015.11.005

    Article  PubMed  Google Scholar 

  18. Metintas M, Ozdemir N, Hillerdal G et al (1999) Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 93(5):349–355. https://doi.org/10.1016/s0954-6111(99)90318-9

    Article  CAS  PubMed  Google Scholar 

  19. https://data.tuik.gov.tr/Kategori/GetKategori?p=Nufus-ve-Demografi-109. Accessed 26 Aug 2021

  20. Metintas M, Ak G, Dundar E et al (2010) Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 137(6):1362–1368. https://doi.org/10.1378/chest.09-0884

    Article  PubMed  Google Scholar 

  21. Beebe-Dimmer JL, Fryzek JP, Yee CL et al (2016) Mesothelioma in the United States: a surveillance, epidemiology, and end results (seer)-medicare investigation of treatment patterns and overall survival. Clin Epidemiol 8:743–750. https://doi.org/10.2147/CLEP.S105396

    Article  PubMed  PubMed Central  Google Scholar 

  22. Metintas S, Ak G, Bogar F et al (2017) Asbestos knowledge and awareness level in central part of Anatolia. Int J Occup Environ Health 23(3):243–249. https://doi.org/10.1080/10773525.2018.1470789

    Article  CAS  PubMed  Google Scholar 

  23. Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580. https://doi.org/10.1097/SLA.0000000000000903

    Article  PubMed  Google Scholar 

  24. Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5(10):1692–1703. https://doi.org/10.1097/JTO.0b013e3181ed0489

    Article  PubMed  Google Scholar 

  25. Rusch VW, Chansky K, Kindler HL et al (2016) IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions, the IASLC mesothelioma staging project: proposals for the m descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol 11(12):2112–2119. https://doi.org/10.1016/j.jtho.2016.09.124

    Article  PubMed  Google Scholar 

  26. Ak G, Metintas S, Akarsu M et al (2015) The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. BMC Cancer 15:510. https://doi.org/10.1186/s12885-015-1519-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Friedberg JS, Culligan MJ, Tsao AS et al (2019) A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint national cancer institute-international association for the study of lung cancer-mesothelioma applied research foundation taskforce. J Thorac Oncol 14(8):1343–1353. https://doi.org/10.1016/j.jtho.2019.04.029

    Article  PubMed  Google Scholar 

  28. Woolhouse I, Bishop L, Darlison L et al (2018) British thoracic society guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73(Suppl 1):i1–i30. https://doi.org/10.1136/thoraxjnl-2017-211321

    Article  PubMed  Google Scholar 

  29. Taioli E, Wolf AS, Camacho-Rivera M et al (2015) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. PLoS ONE 10(12):e0145039. https://doi.org/10.1371/journal.pone.0145039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey

    Selma Metintas, Guntulu Ak, Emine Dundar & Muzaffer Metintas

  2. Medical Faculty Department of Public Health, Eskisehir Osmangazi University, Eskisehir, Turkey

    Selma Metintas

  3. Medical Faculty Department of Chest Disease, Eskisehir Osmangazi University, 26000, Eskisehir, Turkey

    Guntulu Ak & Muzaffer Metintas

  4. Medical Faculty Department of Pathology, Eskisehir Osmangazi University, Eskisehir, Turkey

    Emine Dundar

Authors
  1. Selma Metintas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guntulu Ak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emine Dundar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muzaffer Metintas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guntulu Ak.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Metintas, S., Ak, G., Dundar, E. et al. What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey. Int J Clin Oncol 27, 1202–1211 (2022). https://doi.org/10.1007/s10147-022-02168-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-022-02168-y

Keywords

Search

Navigation